恩替卡韦治疗HBeAg阳性慢性乙型肝炎的临床疗效观察  

Clinical Curative Effects of on Entacavir HbeAg Positive Treatment of Chronic Hepatitis B

作　　者：赵兴忠[1,2] 过小叶[1,2] 

机构地区：[1]无锡市第五人民医院 [2]无锡市传染病医院药剂科,无锡214005

出　　处：《中国医药导刊》2012年第10期1783-1783,1785,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨恩替卡韦(ETV)治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法:选择我院收治的164例HBeAg阳性慢性乙型肝炎患者,分为两组各82例:观察组给予恩替卡韦治疗;对照组给予阿德福韦酯(ADV)治疗,比较两组患者的临床疗效。结果:用药治疗1年后,观察组患者HBV DNA转阴率为81.7%,显著高于对照组的41.5%,组间差异有统计学意义(P<0.05);两组的ALT复常率与HBeAg转阴率比较,差异无统计学意义(P>0.05)。对照组2例患者在治疗过程中出现现外周血白细胞减少症,给予口服苦参素治疗后,症状得以缓解。结论:与阿德福韦酯相比较,恩替卡韦抑制血清中乙肝病毒复制的力度更强,耐药率低,且具有较高的安全性,故可作为一种有效的抗乙型肝炎病毒药物广泛应用于临床治疗HBeAg阳性慢性乙型肝炎患者。Objective：To study on entacavir（ETV） HBeAg positive treatment of chronic hepatitis b clinical curative effect.Methods：choose 164 cases were our HBeAg positive chronic hepatitis b patients,divided into two groups： the observation group give on entacavir treatment;The control group give adefovir dipivoxil（ADV） treatment,compared with two groups of patients with clinical curative effect.Results：medicine 1 years later,the observation group patients HBV DNA turn Yin rate was 81.7%,significantly higher than those in the control group,41.5% of the difference between the groups was statistically significant（P0.05）;The two groups of ALT after often rate and turn HBeAg rate quite,the difference was not statistically significant（P0.05）.The control group 2 patients in the treatment process in peripheral blood disease is leukopenia,give oral bitter and grain after treatment,symptoms ease.Conclusion：and adefovir compare,on entacavir inhibit serum hepatitis b virus replication of strength,stronger,low resistance and high security,it can be as a kind of effective resistance to hepatitis b virus drugs are widely used in the clinical treatment HBeAg positive patients with chronic hepatitis b.

关 键 词：慢性乙型肝炎 恩替卡韦 阿德福韦酯 临床疗效 

分 类 号：R512.62[医药卫生—内科学]